TECHNOLOGY
Kaipharm has contributed to the pharma industry's next-generation based on AI drug discovery technology
and production of drug-induced transcriptome data.
KMAP
~3K approved drugs treatment
~50K drug-induced transcriptomic profiling
Reference database established with own facilities
KMAP Express
Drug candidate’s mode of action interpretation service
Three-month-process from RNA-seq production to analysis
Drug repositioning, new indication discovery, and etc.
